Study on the safety of antimalarial combination between piperaquin and dihydroartemisinin manufactured in Vietnam
- Author:
Le Khanh Thuan
- Publication Type:Journal Article
- Keywords:
Malaria
- MeSH:
Malaria;
Therapeutics;
Artemisinins
- From:Pharmaceutical Journal
2005;0(11):16-20
- CountryViet Nam
- Language:Vietnamese
-
Abstract:
The sub-chronic toxicity of an antimalaria combination between piperaquine phosphate (PQP) and dihydroartemisinin (DHA) at the doses of 64 and 100 mg of (PQP+DHA)/kg of body weight/day for 28 consecutive days in rabbits was investigated in this study. Results: rabbits acted and ate normally. At the doses of 64 mg of (PQP+DHA)/kg/day x 28 consecutive days, the body weights of rabbits increased statistical significantly at day N28 compared to days before using the combination (p<0.05). At the doses of (PQP+DHA) 100 mg/kg/day x 28 consecutive days, the weights of rabbits increased statistically at day 14 and 28. At dose of 64 mg PQP+DHA/kg/day x 28 day, biochemical indicators (SGOT, SGPT, creatinin, protein and bilirubin) and hematological indicators (erythrocytes, leukocytes, leukocyte formula and hemoglobin) did not change significantly (p>0.05) after 28 days. At dose of 100 mg PQP+DHA/kg/day x 28 days, biochemical indicators (SGOT, SGPT, creatinin, protein and bilirubin) and hematological indicators (hemoglobin, erythrocytes, leukocytes, neutrophils and lymphocytes) did not change significantly (p>0.05) after 28 days but protein and monocytes increased significantly (p<0.05) on day 28
